NCT02411786View on ClinicalTrials.gov

A Phase I Study of a DNA Vaccine Encoding Androgen Receptor Ligand-Binding Domain (AR LBD) +/-GMCSF

PHASE1CompletedINTERVENTIONAL
Enrollment

40

Participants

Timeline

Start Date

August 24, 2015

Primary Completion Date

May 1, 2019

Study Completion Date

November 28, 2020

Conditions
Prostate Cancer
Interventions
BIOLOGICAL

pTVG-AR

Given ID

BIOLOGICAL

gm-csf

Given ID

Trial Locations (3)

53792

University of Wisconsin Carbone Cancer Center, Madison

98109

University of Washington Seattle Cancer Care Alliance, Seattle

08903

Cancer Institute of New Jersey, New Brunswick

Sponsors
All Listed Sponsors
collaborator

Madison Vaccines Incorporated

INDUSTRY

lead

University of Wisconsin, Madison

OTHER